IGA Nephropathy Treatment Market Overview
As per MRFR analysis, the IGA Nephropathy Treatment Market Size was estimated at 1.69 (USD Billion) in 2022. The IGA Nephropathy Treatment Market is expected to grow from 1.81 (USD Billion) in 2023 to 3.2 (USD Billion) by 2032. The IGA Nephropathy Treatment Market CAGR (growth rate) is expected to be around 6.57% during the forecast period (2024 - 2032).
The Global IGA Nephropathy Treatment Market is characterized by significant unmet medical needs and a robust pipeline of novel therapies. The rising prevalence of IGA nephropathy, a rare but severe kidney disease, is a key market driver.
The growing awareness of the disease and the availability of advanced diagnostic techniques contribute to early detection and timely treatment.
Pharmaceutical companies focus on developing innovative therapies, including monoclonal antibodies, immunosuppressants, and anti-inflammatory agents, to address unmet needs in the treatment of IGA nephropathy.
These novel treatments aim to improve efficacy and reduce adverse effects, creating opportunities for market growth.
Recent trends in the IGA Nephropathy Treatment Market include personalized medicine approaches, biomarker-driven drug development, and the exploration of combination therapies. Personalized medicine allows for tailored treatment strategies based on individual patient characteristics, while biomarker-driven drug development identifies specific targets for therapeutic intervention.
Combination therapies aim to enhance treatment efficacy and overcome resistance mechanisms. These trends reflect the ongoing advancements and the dynamic nature of the IGA Nephropathy Treatment Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
IGA nephropathy is a chronic kidney disease induced by the deposition of IGA immune complexes in the glomeruli. The glomeruli are the tiny filtering units of the kidney structure and are essential for keeping the blood composition correct.
Nephropathy is another word for kidney damage. IGA nephropathy is the most prevalent primary glomerulonephritis worldwide, with an incidence of 1 to 2.5 cases per 100,000 populations. The global IGA Nephropathy Treatment Market is driven majorly by the increasing prevalence of IGA Nephropathy.
The primary aspects accountable for the increasing occurrence are immune system-mediated abnormalities of kidney function, tremendous genetic propensity, environmental factors, and infectious agents.
Moreover, the augmented consciousness about this chronic kidney disease and better diagnosis are also factors that are boosting the market.
The Global IGA Nephropathy Treatment Market has witnessed significant technological advancements in recent years, leading to the development of more effective and less invasive treatment options. These advancements include the use of immunosuppressive drugs, such as corticosteroids and mycophenolate mofetil, to suppress the overactive immune response that characterizes IGA nephropathy.
Additionally, the advent of biologics, such as rituximab and belimumab, has provided targeted therapies that specifically inhibit the production of IGA antibodies.
Furthermore, minimally invasive procedures, such as laparoscopic and robotic-assisted surgery, have reduced the risks and recovery time associated with traditional open surgeries.
Personalized medicine, also known as precision medicine, involves tailoring medical treatment to the individual characteristics of each patient. In the context of IGA nephropathy, personalized medicine approaches consider factors such as genetic makeup, disease severity, and response to previous treatments.
The growing demand for personalized medicine in the Global IGA Nephropathy Treatment Market is driven by the need for more effective and targeted therapies that optimize patient outcomes.
By understanding the unique molecular and genetic underpinnings of each patient's disease, healthcare providers can select the most appropriate treatment strategies and improve the chances of successful disease management.
The Global IGA Nephropathy Treatment Market is segmented by Treatment Type into Immunosuppressive Therapy, Plasmapheresis, Dialysis, and Kidney Transplant. Among these segments, Immunosuppressive Therapy held the largest market share in 2023, followed by Plasmapheresis. Dialysis is expected to witness the highest growth rate during the forecast period.
Immunosuppressive Therapy segment accounted for approximately 55% of the Global IGA Nephropathy Treatment Market revenue in 2023. The growth of this segment can be attributed to the increasing adoption of immunosuppressive drugs, such as mycophenolate mofetil, azathioprine, and cyclosporine, for the treatment of IGA Nephropathy.
The plasmapheresis segment is expected to register a CAGR of 6.7% during the forecast period. The growth of this segment can be attributed to the increasing awareness about plasmapheresis as a treatment option for IGA Nephropathy and the rising number of plasmapheresis centers worldwide.
The dialysis segment is expected to witness the highest growth rate of 7.1% during the forecast period. The growth of this segment can be attributed to the increasing incidence of IGA Nephropathy and the rising demand for dialysis services in developing countries.
The Kidney Transplant segment is expected to register a CAGR of 5.9% during the forecast period. The growth of this segment can be attributed to the increasing number of kidney transplants performed worldwide and the rising success rate of kidney transplants.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Global IGA Nephropathy Treatment Market is segmented by disease severity into mild, moderate, and severe. Among these segments, the severe segment is expected to hold the largest market share in 2023, owing to the increasing prevalence of chronic kidney disease and the need for intensive treatment options.
The moderate segment is also expected to witness significant growth due to the rising incidence of IGA nephropathy and the availability of effective treatment options. The mild segment is expected to have a relatively smaller market share, as patients with mild disease often do not require extensive treatment.
Overall, the Global IGA Nephropathy Treatment Market is expected to register a CAGR of 6.57% during the forecast period, driven by the increasing prevalence of kidney diseases and the development of new and effective treatment options.
The Global IGA Nephropathy Treatment Market segmentation by Patient Type includes Adult and Pediatric. In 2023, the adult segment accounted for a larger market share due to the higher prevalence of IGA nephropathy in adults compared to children.
The growing geriatric population and the increasing incidence of chronic kidney disease in adults are key factors driving the growth of this segment. The pediatric segment is expected to witness a steady growth rate during the forecast period due to the increasing awareness of IGA nephropathy in children and the development of new treatment options specifically tailored to their needs.
By 2032, the Global IGA Nephropathy Treatment Market for the pediatric segment is projected to reach a valuation of USD 0.45 billion, exhibiting a CAGR of 6.8%.
The Global IGA Nephropathy Treatment Market is segmented into North America, Europe, APAC, South America, and MEA.
North America holds the largest share of the market due to the high prevalence of IGA nephropathy and the availability of advanced treatment options. Europe is the second-largest market, followed by APAC.
The APAC region is expected to grow at the highest CAGR during the forecast period due to the increasing incidence of IGA nephropathy and the growing adoption of new therapies.
South America and MEA are expected to experience moderate growth over the forecast period.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
IGA Nephropathy Treatment Market Key Players and Competitive Insights:
Major players in the IGA Nephropathy Treatment Market are focusing on developing new and innovative therapies to address the unmet medical needs of patients. Leading IGA Nephropathy Treatment Market players are investing heavily in research and development to expand their product portfolios and gain a competitive edge.
The IGA Nephropathy Treatment Market development pipeline is robust, with several promising therapies in late-stage clinical trials. These therapies have the potential to significantly improve the treatment outcomes for patients with the IGA Nephropathy Treatment Market.
The competitive landscape of the IGA Nephropathy Treatment Market is expected to intensify further as new therapies enter the market.
Chugai Pharmaceutical Co., Ltd. is a leading IGA Nephropathy Treatment Market player with a strong focus on developing innovative therapies for rare diseases. The company's portfolio includes Renvela (renin inhibitor) and Enspryng (angiotensin II receptor blocker), which are approved for the treatment of IGA Nephropathy Treatment Market.
Chugai Pharmaceutical Co., Ltd. is also developing several other therapies for the IGA Nephropathy Treatment Market, including an anti-fibrotic agent and a selective androgen receptor modulator.
Bristol Myers Squibb is another major player in the IGA Nephropathy Treatment Market. The company's portfolio includes Kerydin (anakinra), which is approved for the treatment of the IGA Nephropathy Treatment Market.
Bristol Myers Squibb is also developing several other therapies for the IGA Nephropathy Treatment Market, including an anti-inflammatory agent and a JAK inhibitor.
Key Companies in the IGA Nephropathy Treatment Market Include:
IGA Nephropathy Treatment Market Developments
The increasing prevalence of IGA nephropathy, rising demand for minimally invasive procedures, and growing awareness about early diagnosis are driving the market growth.
Key developments include the FDA approval of Koselugo (selumetinib) for treating IGA nephropathy, as well as ongoing clinical trials evaluating novel therapies such as atacicept and sparsentan.
Strategic collaborations and acquisitions, such as the partnership between Kyowa Kirin and Visterra, are also shaping the market landscape.
| Report Attribute/Metric | Details |
| Market Size 2022 | 1.69 (USD Billion) |
| Market Size 2023 | 1.81 (USD Billion) |
| Market Size 2032 | 3.2 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 6.57% (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Merck Co., Inc., Pfizer Inc., Johnson Johnson Services, Inc., Novartis AG, Baxter International Inc., Fresenius Medical Care AG Co. KGaA, Otsuka Pharmaceutical Co., Ltd., AbbVie Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., F. HoffmannLa Roche Ltd. |
| Segments Covered | Treatment Type, Disease Severity, Patient Type, Regional |
| Key Market Opportunities | 1 Increasing prevalence of IGA nephropathy 2 Technological advancements 3 Growing demand for minimally invasive procedures 4 Rising awareness 5 Expansion of the generic drug market |
| Key Market Dynamics | Rising prevalence of IGA nephropathy Technological advancements in treatment modalities Growing geriatric population Increasing healthcare expenditure Emergence of novel therapies |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Global IGA Nephropathy Treatment Market size was valued at USD 1.81 billion in 2023 and is expected to reach USD 3.2 billion by 2032, exhibiting a CAGR of 6.57% during the forecast period (2024-2032).
North America is expected to dominate the Global IGA Nephropathy Treatment Market throughout the forecast period. The large patient population, well-developed healthcare infrastructure, and high adoption rates of advanced treatment modalities contribute to the region's dominance
The rising prevalence of IGA nephropathy, increasing awareness of the disease, and the development of new and effective treatment options are the key factors driving the growth of the Global IGA Nephropathy Treatment Market
IGA Nephropathy Treatment is primarily used for the treatment of IGA nephropathy, a type of kidney disease characterized by the deposition of immunoglobulin A (IGA) in the glomeruli of the kidneys
The key competitors in the Global IGA Nephropathy Treatment Market include F. Hoffmann-La Roche AG, Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, and Merck Co., Inc. These companies offer a range of treatment options for IGA nephropathy, including immunosuppressive drugs, corticosteroids, and biologics
The Global IGA Nephropathy Treatment Market is expected to exhibit a CAGR of 6.57% during the forecast period (2024-2032).
The major challenges faced by the Global IGA Nephropathy Treatment Market include the high cost of treatment, the lack of awareness about the disease, and the limited availability of effective treatment options
The Global IGA Nephropathy Treatment Market is expected to reach USD 3.2 billion by 2032
The major trends in the Global IGA Nephropathy Treatment Market include the increasing adoption of targeted therapies, the development of novel drug delivery systems, and the growing focus on personalized medicine
The major unmet needs in the Global IGA Nephropathy Treatment Market include the need for more effective treatment options, the need for improved diagnostic tools, and the need for better patient education and support
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
